Global Pre-Implantation Genetic Diagnosis (PGD) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Pre-Implantation Genetic Diagnosis (PGD) Market Research Report 2024
Pre-Implantation Genetic Diagnosis (PGD) is the genetic profiling of embryos prior to implantation (as a form of embryo profiling), and sometimes even of oocytes prior to fertilization.
According to MRAResearch’s new survey, global Pre-Implantation Genetic Diagnosis (PGD) market is projected to reach US$ 137.1 million in 2033, increasing from US$ 101.7 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pre-Implantation Genetic Diagnosis (PGD) market research.
When used to screen for a specific genetic disease, PGD main advantage is that it avoids selective abortion, as the method makes it highly likely that the baby will be free of the disease under consideration. PGD thus is an adjunct to assisted reproductive technology, and requires in vitro fertilization (IVF) to obtain oocytes or embryos for evaluation. Embryos are generally obtained through blastomere or blastocyst biopsy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pre-Implantation Genetic Diagnosis (PGD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche
Genea Limited
Quest Diagnostics
Illumina, Inc.
Natera, Inc.
Cooper Medical, Inc.
LabCorp
California Pacific Medical Center (CPMC)
Thermo Fisher Scientific Inc.
IGENOMIX
Reproductive Genetic Innovations
CombiMatrix
Segment by Type
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pre-Implantation Genetic Diagnosis (PGD) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Pre-Implantation Genetic Diagnosis (PGD) market is projected to reach US$ 137.1 million in 2033, increasing from US$ 101.7 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pre-Implantation Genetic Diagnosis (PGD) market research.
When used to screen for a specific genetic disease, PGD main advantage is that it avoids selective abortion, as the method makes it highly likely that the baby will be free of the disease under consideration. PGD thus is an adjunct to assisted reproductive technology, and requires in vitro fertilization (IVF) to obtain oocytes or embryos for evaluation. Embryos are generally obtained through blastomere or blastocyst biopsy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pre-Implantation Genetic Diagnosis (PGD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Genea Limited
Quest Diagnostics
Illumina, Inc.
Natera, Inc.
Cooper Medical, Inc.
LabCorp
California Pacific Medical Center (CPMC)
Thermo Fisher Scientific Inc.
IGENOMIX
Reproductive Genetic Innovations
CombiMatrix
Segment by Type
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others
Segment by Application
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pre-Implantation Genetic Diagnosis (PGD) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source